OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Ahead of its presentation at the JP Morgan Healthcare Conference in San Francisco, Oxford Immunotec Global PLC (Nasdaq:OXFD) this morning announced that based on preliminary unaudited financial data, the Company expects total revenue for the fourth quarter of 2013 will be between $10.1 and $10.5 million. For fiscal 2013, the Company expects total revenue of between $38.6 and $39.0 million. These preliminary results are subject to completion of the Company’s audit and other financial and accounting procedures.
Help employers find you! Check out all the jobs and post your resume.
